EFPIA statement on the EU-Turkey WTO Case on Pharmaceuticals
Yesterday’s appeal arbitration award by the WTO in the case the EU brought against Turkey on pharmaceutical products, ensures non-discriminatory treatment of EU pharmaceutical exports to Turkey and continued access for Turkish patients to innovative and effective medicines, irrespective of the place of their manufacturing. EFPIA welcomes the swift completion of the appeal arbitration process, and the positive signal this sends for an effective dispute settlement system, one of the core elements underpinning the rules-based global trading system. We reiterate our position in favour of an open and rules-based trading system which best supports the resilience and efficiency of global pharmaceutical supply chains. EFPIA Members stand ready to work closely with the Government of Turkey with a view to continue to build an ecosystem enabling innovative medicines to benefit Turkish patients and create value for the Turkish economy.